Gains in NAALADL2 were associated with clinical hallmarks of aggressive prostate cancer, including tumour stage, Gleason grade, reduced time to disease recurrence following radical prostatectomy, increased likelihood of a multi-focal tumour, positive surgical margins and lymph node metastasis28. The gene discussed is NAALADL2; the disease is prostate cancer.